Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Adenocarcinoma

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,978 result(s) found for: Adenocarcinoma. Displaying page 4 of 99.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2015-003397-33 Sponsor Protocol Number: IRST185.02 Start Date*: 2015-10-08
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS
    Full Title: 68Ga-PSMA HBED-PET/CT in the evaluation of the biochemical relapse in patients with a history of prostate cancer radically treated.
    Medical condition: prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10001186 Adenocarcinoma of prostate LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001858-28 Sponsor Protocol Number: 10-14 Start Date*: 2011-08-10
    Sponsor Name:Cancer Trials Ireland
    Full Title: Neo-AEGIS (NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study): Randomised Clinical Trial of neoadjuvant and adjuvant chemotherapy (Investigator...
    Medical condition: Adenocarcinoma of the oesophagus and oesophagastric junction
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DK (Completed) GB (GB - no longer in EU/EEA) FR (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2004-001363-22 Sponsor Protocol Number: TH-CR-302 Start Date*: 2004-12-10
    Sponsor Name:Threshold Pharmaceuticals
    Full Title: A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Best Supportive Care in Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
    Medical condition: Previously treated metastatic pancreatic adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    7.0 10033599 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-001967-26 Sponsor Protocol Number: ACT16444 Start Date*: 2021-09-16
    Sponsor Name:Sanofi aventis recherche & développement
    Full Title: Open-label study of tusamitamab ravtansine (SAR408701) in combination with ramucirumab in participants previously treated for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma with...
    Medical condition: Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001150 Adenocarcinoma gastric PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-001609-81 Sponsor Protocol Number: PH-L19ILGEM-01/07 Start Date*: 2007-11-05
    Sponsor Name:Philogen S.pA.
    Full Title: Phase I/II study of the tumor-targeting human L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine in patients with advanced pancreatic cancer
    Medical condition: Histologically or cytologically confirmed solid cancer of any pathology or adenocarcinoma of the pancreas
    Disease: Version SOC Term Classification Code Term Level
    9.1 10065147 Malignant solid tumor LLT
    9.1 10052747 Adenocarcinoma pancreas LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2022-001752-42 Sponsor Protocol Number: PRESTO Start Date*: 2023-04-13
    Sponsor Name:Frankfurter Institut für Klinische Krebsforschung IKF GmbH
    Full Title: The PRESTO Trial- Organ preservation with durvalumab-based immunotherapy in combination with chemoradiation as definitive therapy for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indi...
    Medical condition: T1-T2N0 esophageal adenocarcinoma including gastroesophageal junction (GEJ) with indication for radical surgery
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10062878 Gastrooesophageal cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005725-29 Sponsor Protocol Number: EGF110656 Start Date*: 2008-05-09
    Sponsor Name:GlaxoSmithKline Research and Development
    Full Title: A Phase III Study of ErbB2 Positive Advanced or Metastatic Gastric or Esophageal Or Gastroesophageal Junction Adenocarcinoma Treated with Capecitabine Plus Oxaliplatin with or without Lapatinib
    Medical condition: Subjects with ErbB2-positive advanced or metastatic gastric or oesophageal or gastro-oesophageal junction adenocarcinoma.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001150 Adenocarcinoma gastric LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) IT (Completed) NL (Ongoing) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002031-92 Sponsor Protocol Number: EX0307 Start Date*: Information not available in EudraCT
    Sponsor Name:Otto-von-Guericke University
    Full Title: Proliferation and differentiation markers, involved in erosive and non-erosive reflux esophagitis, Barrett´s esophagus and esophageal adenocarcinoma.
    Medical condition: Dyspeptic Symptoms GERD (gastroesophageal reflux disease), NERD (non erosive reflux disease), ERD (erosive reflux disease), Barretts esophagus, Adeno-CA of the esophagus
    Disease: Version SOC Term Classification Code Term Level
    9.1 10017885 Gastrooesophageal reflux disease PT
    9.1 10004137 Barrett's oesophagus PT
    9.1 10001173 Adenocarcinoma of esophagus LLT
    9.1 10013949 Dyspeptic signs and symptoms HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-019595-79 Sponsor Protocol Number: UMCNONCO200905 Start Date*: 2010-10-15
    Sponsor Name:University Medical Centre Nijmegen
    Full Title: A randomised phase II study of radio-chemotherapy with or without panitumumab (Vectibix®) in irresectable squamous cell carcinoma or adenocarcinoma of the oesophagus (Panoramic)
    Medical condition: histology proven irresectable squamous cell or adenocarcinoma of the oesophagus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10055476 Esophageal squamous cell carcinoma LLT
    12.1 10055458 Esophageal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023050-37 Sponsor Protocol Number: TRICC-C Start Date*: 2011-05-20
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: A multicenter, randomized, phase II trial: BIBF 1120 vs. placebo in patients receiving oxaliplatin plus fluorouracil and leucovorin (mFOLFOX6) for advanced, chemorefractory metastatic colorectal ca...
    Medical condition: Patients with chemorefractory colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002632-23 Sponsor Protocol Number: IFO21_02 Start Date*: 2021-12-22
    Sponsor Name:ISTITUTI FISIOTERAPICI OSPITALIERI
    Full Title: A proof-of-concept, biomarker-driven, phase-II clinical trial to explore the activity of decitabine repurposing against advanced, refractory, KRAS-dependent pancreatic ductal adenocarcinoma (PDAC):...
    Medical condition: Advanced (locally advanced or metastatic), pre-treated PDAC patients, progressing after at least one and no more than two lines of systemic therapy, whose tumors express a KRAS-dependency signature.
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019602-16 Sponsor Protocol Number: Start Date*: 2011-01-10
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust
    Full Title: A study of lapatinib in combination with oxaliplatin and capecitabine in early HER-2 overexpressing oesophageal and gastric cancers
    Medical condition: Oesophagogastric adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10017758 Gastric cancer LLT
    9.1 10001173 Adenocarcinoma of the oesophagus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-003965-27 Sponsor Protocol Number: OCTO-072 Start Date*: Information not available in EudraCT
    Sponsor Name:University of Oxford
    Full Title: A phase I dose escalation safety study combining the ATR inhibitor M6620 with chemoradiotherapy in oesophageal cancer & other sold cancers using time to event continual reassessment method
    Medical condition: Stage A1 and B: Oesophageal carcinoma Stage A2: Any advanced solid tumours (carcinomas)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2004-000353-38 Sponsor Protocol Number: WX-2003-07-HR Start Date*: 2004-12-20
    Sponsor Name:Wilex AG
    Full Title: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with clear cell RCC and high risk of recurrence
    Medical condition: Renal cell carcinoma of the clear cell type after nephrectomy and no evidence of residual disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038415 Renal cell carcinoma stage unspecified LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) FI (Prematurely Ended) ES (Ongoing) GB (Completed) CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-021118-47 Sponsor Protocol Number: LAOXCAP Start Date*: 2010-10-07
    Sponsor Name:Fundación Hospital de Madrid
    Full Title: Estudio fase II, abierto, multicéntrico, no aleatorizado para evaluar la eficacia y la seguridad de la combinación de lapatinib, oxaliplatino y capecitabina como tratamiento neoadyuvante en pacient...
    Medical condition: pacientes HER2/ErbB2 positivo con adenocarcinoma gástrico, de la unión gastroesofágica o del tercio inferior del esófago en estadio IB - III.
    Disease: Version SOC Term Classification Code Term Level
    13 10001150 Adenocarcinoma gástrico LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-000853-22 Sponsor Protocol Number: CA184-162 Start Date*: 2012-06-13
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A randomized, open-label, two-arm phase II trial comparing the efficacy of sequential ipilimumab versus best supportive care following first-line chemotherapy in subjects with unresectable locally...
    Medical condition: Locally advanced (unresectable) or metastatic adenocarcinoma of the gastric and gastro-esophageal junction
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030137 Oesophageal adenocarcinoma PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-005741-31 Sponsor Protocol Number: AIO-YMO/TRK-0415 Start Date*: 2016-12-02
    Sponsor Name:AIO-Studien-gGmbH
    Full Title: Fostering efficacy of anti – PD-1 – treatment: Nivolumab plus radiotherapy in advanced NSCLC
    Medical condition: metastatic non-squamous Non-Small Cell Lung Cancer (Lung adenocarcinoma metastatic and Large cell lung cancer metastatic)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10069730 Large cell lung cancer metastatic PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10064049 Lung adenocarcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004648-29 Sponsor Protocol Number: C05002 Start Date*: 2005-05-09
    Sponsor Name:Janssen Cilag International, N.V. (Sponsor in European Union)
    Full Title: A Multicenter, Open-label, Phase 2 Study of VELCADE (bortezomib) for Injection in Previously Treated Patients with Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloa...
    Medical condition: Stage IIIB and IV Bronchioloalveolar Carcinoma and Adenocarcinoma with Bronchioloalveolar Features
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002737-38 Sponsor Protocol Number: EUCROSS Start Date*: 2014-05-13
    Sponsor Name:University of Cologne
    Full Title: A phase II trial to evaluate efficacy and safety of crizotinib treatment in advanced adenocarcinoma of the lung harbouring ROS1 translocations
    Medical condition: Adult patients with either firstly diagnosed or relapsed advanced adenocarcinoma of the lung harbouring ROS1 translocation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10025032 Lung adenocarcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001028-21 Sponsor Protocol Number: D6070C00005 Start Date*: 2018-09-19
    Sponsor Name:MedImmune, LLC
    Full Title: A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pa...
    Medical condition: Pancreatic Ductal Adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) ES (Ongoing)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 04 06:28:05 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA